Theravance Biopharma Inc expected to post a loss of 56 cents a share - Earnings Preview

Theravance Biopharma

02/11/2021 02:06

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 3. 
* The George Town, Grand Cayman-based company is expected to
report  a 21.1% decrease in revenue to $14.401 million from
$18.26 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Theravance Biopharma
Inc is for a loss of 56 cents per share. For the same quarter
last year, the company reported a loss of $1.16 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 3 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Theravance
Biopharma Inc is $9​, about 10.8% above​ its last closing price
of $8.03. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -1.02       -1.02      -0.80     Beat    21.8
 Mar. 312021   -1.05       -1.05      -1.24     Missed  -18.3
 Dec. 312020   -1.02       -1.02      -0.92     Beat    9.4​
 Sep. 302020   -0.99       -1.01      -1.16     Missed  -14.5
 ​​Jun.        -0.98       -0.98      -1.00     Missed  -2.4
 302020                                                 
 Mar. 312020   -1.09       -1.07      -1.40     Missed  -30.2​
 Dec. 312019   -1.13       -1.13      -1.17     Missed  -3.4
 Sep. 302019   -1.11       -1.11      -1.05     Beat    5.1
 This summary was machine generated November 2 at 02:05 GMT.  All
figures in US dollars unless otherwise stated